Toggle navigation
Browse
Home
Researchers
Research Departments
Publications
About/Support
ESMO OPEN
Journal
Overview
Research
Identity
Other
View All
Overview
publication venue for
A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-06939999 (PRMT5 inhibitor) in patients with selected advanced or metastatic tumors with high incidence of splicing factor gene mutations
. 9.
2024
Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy
. 5.
2020
Patient-reported outcomes in a phase II, North American study of alectinib in patients with ALK-positive, crizotinib-resistant, non-small cell lung cancer
. 3.
2018
Research
category
ONCOLOGY
Web of Science Category
Identity
International Standard Serial Number (ISSN)
2059-7029
Electronic International Standard Serial Number (EISSN)
2059-7029
Other
journal abbreviation
ESMO OPEN